Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Philip Keiser

Showing results (31-40 of 34) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 34 results.
Journal of Virology|November 30, 2007
Gamma/Delta T-cell functional responses differ after pathogenic human immunodeficiency virus and nonpathogenic simian immunodeficiency virus infectionsDavid A Kosub, Ginger Lehrman, Jeffrey M Milush, et al.
Plos One|November 22, 2013
The clinical impact of continuing to prescribe antiretroviral therapy in patients with advanced AIDS who manifest no virologic or immunologic benefitDavid A Wohl, Michelle A Kendall, Judith Feinberg, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|December 21, 2004
Racial and gender disparities in receipt of highly active antiretroviral therapy persist in a multistate sample of HIV patients in 2001Kelly A Gebo, John A Fleishman, Richard Conviser, et al.
Journal of the Pediatric Infectious Diseases Society|August 31, 2022
Primary and Secondary Attack Rates by Vaccination Status after a SARS-CoV-2 B.1.617.2 (Delta) Variant Outbreak at a Youth Summer Camp-Texas, June 2021Julia M Baker, Melisa M Shah, Michelle O'Hegarty, et al.
Pageof 4

Showing results (31-40 of 34) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 34 results.
Journal of Virology|November 30, 2007
Gamma/Delta T-cell functional responses differ after pathogenic human immunodeficiency virus and nonpathogenic simian immunodeficiency virus infectionsDavid A Kosub, Ginger Lehrman, Jeffrey M Milush, et al.
Plos One|November 22, 2013
The clinical impact of continuing to prescribe antiretroviral therapy in patients with advanced AIDS who manifest no virologic or immunologic benefitDavid A Wohl, Michelle A Kendall, Judith Feinberg, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|December 21, 2004
Racial and gender disparities in receipt of highly active antiretroviral therapy persist in a multistate sample of HIV patients in 2001Kelly A Gebo, John A Fleishman, Richard Conviser, et al.
Journal of the Pediatric Infectious Diseases Society|August 31, 2022
Primary and Secondary Attack Rates by Vaccination Status after a SARS-CoV-2 B.1.617.2 (Delta) Variant Outbreak at a Youth Summer Camp-Texas, June 2021Julia M Baker, Melisa M Shah, Michelle O'Hegarty, et al.
Pageof 4